Murphy Pohlad Asset Management LLC Reduces Position in Pfizer Inc. $PFE

Murphy Pohlad Asset Management LLC cut its position in Pfizer Inc. (NYSE:PFE) by 23.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 62,795 shares of the biopharmaceutical company’s stock after selling 19,641 shares during the period. Murphy Pohlad Asset Management LLC’s holdings in Pfizer were worth $1,564,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently modified their holdings of the company. Horizon Financial Services LLC grew its position in shares of Pfizer by 174.8% in the 4th quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 645 shares during the last quarter. YANKCOM Partnership purchased a new position in shares of Pfizer in the 4th quarter valued at $28,000. HFM Investment Advisors LLC grew its position in shares of Pfizer by 61.0% in the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 427 shares during the last quarter. Darwin Wealth Management LLC purchased a new position in shares of Pfizer in the 2nd quarter valued at $32,000. Finally, Torren Management LLC purchased a new position in shares of Pfizer in the 4th quarter valued at $34,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms recently commented on PFE. Bank of America dropped their target price on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a research report on Thursday, April 9th. Royal Bank Of Canada reaffirmed an “underperform” rating and issued a $25.00 target price on shares of Pfizer in a research report on Monday, April 20th. CICC Research began coverage on shares of Pfizer in a research report on Thursday, April 16th. They issued an “outperform” rating and a $33.00 target price on the stock. Wolfe Research reaffirmed an “underperform” rating and issued a $26.00 target price on shares of Pfizer in a research report on Thursday, May 14th. Finally, Zacks Research raised shares of Pfizer from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 24th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, twelve have given a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat, Pfizer has a consensus rating of “Hold” and an average target price of $28.61.

Pfizer Trading Up 0.1%

Shares of Pfizer stock opened at $25.92 on Tuesday. Pfizer Inc. has a 1 year low of $22.88 and a 1 year high of $28.75. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25. The company has a market capitalization of $147.72 billion, a P/E ratio of 19.79 and a beta of 0.35. The company’s fifty day moving average is $26.84 and its two-hundred day moving average is $26.25.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.72 by $0.03. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The company had revenue of $14.45 billion for the quarter, compared to the consensus estimate of $13.84 billion. During the same period last year, the firm posted $0.92 EPS. Pfizer’s revenue for the quarter was up 5.4% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Analysts forecast that Pfizer Inc. will post 2.99 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 12th. Stockholders of record on Friday, May 8th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.6%. The ex-dividend date is Friday, May 8th. Pfizer’s dividend payout ratio (DPR) is 131.30%.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.